The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).
 
Hye Ryun Kim
Speakers' Bureau - ABL Bio; Ono Pharmaceutical; Roche/Genentech
 
Omar Saavedra
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Andres Cervantes
Consulting or Advisory Role - Amgen (Inst); Foundation Medicine (Inst); Merck Serono (Inst); Roche (Inst); Transgene (Inst)
Research Funding - Actuate Therapeutics (Inst); Adaptimmune (Inst); Amcure (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer (Inst); BeiGene (Inst); BMSi (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)
Other Relationship - Annals of Oncology; Cancer Treatment Reviews; ESMO Open
 
Iwona A. Lugowska
Honoraria - Agenus; Amgen; AstraZeneca; BeiGene; BMS; Celon Pharma; Cullinan Oncology; Jacobio; Janssen; Loxo; Macrogenics; Menarini; MSD; Pfizer; Rhizen Pharmaceuticals; ROCHE; Sanofi; Sanofi; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AGENUS (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - BMS
 
Arjun Oberoi
No Relationships to Disclose
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; Exelixis; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Jacob Stephen Thomas
Consulting or Advisory Role - Kura Oncology; Tasly Pharmaceuticals
 
Wojciech Rogowski
No Relationships to Disclose
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Basilea; CureTeq; Ellipses Pharma; Genmab; GlaxoSmithKline; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Astex Pharmaceuticals (Inst); Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Byoung Yong Shim
Consulting or Advisory Role - ABION; AstraZeneca; Guardant Health; J Ints Bio; Pfizer; Takeda
Research Funding - Yuhan
 
Eric Christenson
Consulting or Advisory Role - Seres Therapeutics
Research Funding - Haystack Oncology; Pfizer
Other Relationship - Natera
(OPTIONAL) Uncompensated Relationships - Brenus Pharma
 
Valentina Boni
No Relationships to Disclose
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Medscape; MSD Oncology; Novartis; Oncohost; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Abion; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Mirati Therapeutics; MSD Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Merck
 
Ramon Yarza
No Relationships to Disclose
 
Ulrike Gaertner
Employment - Affimed NV
 
Sarah Lutkewitz
No Relationships to Disclose
 
Daniel Shuetz
Employment - Octapharma USA
Stock and Other Ownership Interests - Octapharma USA
 
Kerstin Pietzko
Employment - Octapharma USA
Stock and Other Ownership Interests - Octapharma USA
 
Michael Emig
Employment - Affimed Therapeutics; Lilly; Merck KGaA
Stock and Other Ownership Interests - Lilly
 
Daniela Morales Espinosa
Employment - Affimed Therapeutics
Consulting or Advisory Role - Takeda